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INTRODUCTION 
Osteoarthritis (OA) is a degenerative 
joint disease that can cause severe pain in those 
affected. Currently, there are no therapeutic 
drugs available to treat osteoarthritis. While total 
joint arthroplasties (TJA) allow for improved 
function, there are no less invasive, yet effective 
procedures that can be done for patients 
unwilling or unable to undergo major surgery. 
Platelet-rich plasma (PRP) has been 
shown to reduce the symptoms of OA when 
injected into the affected joint. Patients treated 
by this method alone have improved self-
reported pain (at least a 50% reduction from 
original value) as well as lower extremity 
function. While the effects of PRP treatment on 
OA have been positive, treatment with SVF 
offers additional benefits that PRP alone cannot. 
SVF contains a significant amount of 
mesenchymal stem cells (MSC), which have 
great potential in the field of regenerative 
medicine. The potential to generate new 
cartilage in osteoarthritic joints goes beyond 
treatment of the symptoms offering a reversal of 
the harmful pathology. Considering the positive 
results seen from both SVF and PRP treatment, 
the reduced risk of surgical complication when 
compared to TJA, and the possibility for equal 
or greater pain improvement and joint 
functionality compared to TJA, we believed it 
would be advantageous to investigate a 
combined PRP and SVF therapy for relief of 
both mild and advanced stage OA. 
MATERIAL AND METHODS 
 Patients with moderate osteoarthritis 
presenting with severe hip pain were selected for 
treatment. After a detailed informed consent 
process, patients were taken to the operating 
room for the proposed combination treatment. 
SVF was isolated using liposuction equipment, 
and PRP and SVF were centrifuged 
independently. With ultrasound guidance, a 
mixture of PRP (10mL) and SVF (10mL) was 
injected into the osteoarthritic hip joints of 
patients under general anesthesia. The Western 
Ontario and McMaster Universities Arthritis 
Index (WOMAC) scale was used to assess 
patients preoperatively and postoperatively to 
assess pain improvement. 
RESULTS 
 WOMAC scores were 67/96 
preoperatively, and 17/96 at five weeks post-op. 
This indicated a decrease in pain and increased 
mobility. The procedure was both efficient—
taking approximately one hour of operative 
time—and cost effective. No intraoperative nor 
postoperative morbidities were found.  
CONCLUSION 
 This new combination therapy offers a 
minimally invasive, low-risk and high-
satisfaction treatment for osteoarthritic joints. 
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